Aptevo Therapeutics Inc. - APVO
About Gravity Analytica
Recent News
- 04.22.2025 - Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 04.21.2025 - Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 04.04.2025 - Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- 04.03.2025 - Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- 03.20.2025 - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Recent Filings
- 04.18.2025 - D Notice of Exempt Offering of Securities
- 04.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
- 04.10.2025 - PRE 14A Other preliminary proxy statements
- 04.09.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
- 04.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
- 04.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
- 04.04.2025 - 424B4 Prospectus [Rule 424(b)(4)]
- 04.04.2025 - 8-K Current report
- 04.04.2025 - EX-99.1 EX-99.1
- 04.01.2025 - S-1/A General form for registration of securities under the Securities Act of 1933